Fulcrum Therapeutics FULC 深 沪
等待开盘 10-06 09:30:00 美东时间
3.71
+0.020
+0.54%
华盛通- 最 高3.915
- 今 开3.70
- 成交量 105.44万股
- 最 低 3.65
- 昨 收 3.69
- 总市值 15.15万
- 52周最高 15.7399
- 市盈率 静 --
- 换手率 2581.26%
- 52周最低 2.83
- 委 比 14.01%
- 总股本 4.08万
- 历史最高 33.098
- 量 比 0.71
- 振 幅 7.18%
- 历史最低 1.10
- 每 手 1
- 风险率 3.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Downgrades Fulcrum Therapeutics to Underweight
JP Morgan downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Underweight.
06-03 23:29
FULC Stock Crashes After Hours: What Investors Need To Know
Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.
06-02 13:50
Fulcrum Therapeutics Launches Strategic Alternatives Review To Maximize Shareholder Value
― Company to explore strategic alternatives to maximize stockholder value ―CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical
06-02 04:17
Earnings Scheduled For April 27, 2026
Companies Reporting Before The Bell • Alliance Res Partners (NASDAQ:ARLP) is es...
04-27 19:11
Fulcrum Therapeutics Q4 EPS $(0.31), Inline
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
02-24 20:42
Fulcrum Acquires Environmental Software Firm Wildnote; Financial Terms Not Disclosed
Fulcrum, the AI-powered field process management and data collection platform, today announced it has acquired Wildnote, an environmental software company focused on regulatory compliance with field data capture and
02-17 23:19
Fulcrum Therapeutics Stock Rally Ignited By Promising Sickle Cell Results
Fulcrum Therapeutics stock surges on Monday after releasing positive results from Phase 1b trial of pociredir in sickle cell disease.
2025-12-09 02:06
Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-12-09 01:46
Market-Moving News for December 8th
FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically
2025-12-08 20:34
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics granted 70,000 stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The options have an exercise price of $6.96 per share, vest over four years, and expire in ten years. The company specializes in developing small molecules for rare genetic diseases.
2025-06-06 20:30
